GlassScriptPhysician profile
Akshar Kalola
NPI 1851970081
$1,696.01
in general payments reported to CMS, 2019-2025
18 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $683 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.03 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.41 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $306.84 | 2024-2025 | |
| Eisai INC. | $111.97 | 2024-2025 | |
| Tempus Ai, INC | $99.36 | 2024-2025 | Xt Cdx |
| Sobi, INC | $77.82 | 2025 | Doptelet, Vonjo |
| Astellas Pharma US INC | $69.99 | 2024 | |
| Lilly USA, LLC | $66.86 | 2024-2025 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $54.80 | 2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $53.13 | 2025 | |
| Incyte Corporation | $48.69 | 2025 | Jakafi, Niktimvo |
| Genentech USA, INC. | $46.94 | 2024-2025 | Venclexta, Polivy |
| Merck Sharp & Dohme LLC | $46.40 | 2024-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $35.87 | 2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $33.05 | 2025 | Libtayo |
| Glaxosmithkline, LLC. | $26.58 | 2024 | Ojjaara |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.61 | 2025 | Ultomiris |
| Amgen INC. | $21.73 | 2024 | Blincyto |
| Novocure INC. | $20.96 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshar Kalola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.